Trial Profile

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 19 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lebrikizumab (Primary)
Indications Atopic dermatitis
Focus Adverse reactions
Acronyms ADjoin
Sponsors Dermira; Eli Lilly and Company

Most Recent Events

21 May 2025 Status changed from active, no longer recruiting to completed.
07 Mar 2025 Three year data of monthly maintenance injection of EBGLYSS from this long term long-term extension study will be presented at the American Academy of Dermatology (AAD) Annual Meeting, taking place March 7-11 in Orlando.
07 Mar 2025 Results presented in the Eli Lilly and Company media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com